Sp1274
UC RESULTS: EXPLORING CLINICAL OUTCOMES AND LONG-TERM SAFETY OF A JAK INHIBITOR
Date
May 7, 2023
Society: DDW
1) Examine clinical and objective treatment goals 2) Overview of efficacy in patients with moderate to severe Ulcerative Colitis 3) Overview of rapid symptom relief in patients with moderate to severe UC 4) Review long-term safety across six indications including patients with moderate to severe UC Sponsored by AbbVie
1) Examine clinical and objective treatment goals 2) Overview of efficacy in patients with moderate to severe Ulcerative Colitis 3) Overview of rapid symptom relief in patients with moderate to severe UC 4) Review long-term safety across six indications including patients with moderate to severe UC Sponsored by AbbVie
Presenter
Tracks
Related Products
THE SYMPTOM EXPERIENCE OF PERSONS WITH CROHNS DISEASE WITH ACTIVE DISEASE COMPARED TO THOSE WITH INACTIVE DISEASE-THE MAGIC IN IMAGINE STUDY
BACKGROUND: The Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE) Strategy for Patient Oriented Research (SPOR) Chronic Disease Network is conducting a five-year multicenter prospective observational cohort study, Mind And Gut Interactions Cohort (…
ASSOCIATION OF ULTRA-PROCESSED FOODS WITH GUT MICROBIOME, GUT PERMEABILITY, AND FECAL CALPROTECTIN IN HEALTHY FIRST DEGREE RELATIVE OF CD PATIENTS
The incidence of inflammatory bowel disease (IBD) is increasing globally. Epidemiological studies suggest an association between consumption of ultra-processed foods (UPFs) and IBD risk…
ASSOCIATION OF AIR POLLUTION WITH RISK OF CROHN’S DISEASE AND BIOMARKERS OF CD RISK IN THE CCC-GEM PROJECT
Incidence of Crohn's disease(CD) is increasing worldwide. Previous studies suggest that exposure to air pollutants may contribute to the risk of CD…
ADDITIONAL RISANKIZUMAB THERAPY IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO DID NOT ACHIEVE CLINICAL RESPONSE TO INITIAL 12-WEEK INDUCTION THERAPY: AN ANALYSIS OF PHASE 3 INSPIRE AND COMMAND STUDIES
BACKGROUND: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148)…
